Sonali Thosani

Dr. Sonali Thosani

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
VBVeronica Brady
Veronica Brady
STSonali Thosani
Sonali Thosani
SZShouhou Zhou
Shouhou Zhou
RBRoland Bassett
Roland Bassett
NBNaifa Lamki Busaidy
Naifa Lamki Busaidy
VLVictor R Lavis
Victor R Lavis
Background: Hyperglycemia occurs in cancer patients receiving high-dose steroids with cyclophosphamide, doxorubicin, vincristine, and dexamethasone (hyper-CVAD) protocol. The purpose of our study was to determine insulin requirements in patients with hyperglycemia on hyper-CVAD therapy using a systematic algorithm. Subjects and Methods: We did a retrospective chart review of 23 leukemia inpatients with hyperglycemia (two glucose values >250 mg/dL) on hyper-CVAD chemotherapy managed by the Endocrine Diabetes Inpatient Team algorithm. We reviewed demographic and glycemic data, insulin dosages, and use of oral hypoglycemic agents. Using our algorithm, the dose of insulin for each patient was titrated daily and with each subsequent cycle of hyper-CVAD. Results: Ninety-one percent of patients had known diabetes. The median body mass index was 32.5 (range, 21.6–40.9) kg/m 2 , and median age was 61 (range, 40–80) years. The overall trend in glucose values across cycles showed a statistically significant decrease with each subsequent cycle of hyper-CVAD. Hyperglycemia accounted for 81% of glucose measurements in the first cycle and 60% of glucose values in the last cycle. Patients received 1–1.3 units/kg of insulin per cycle, and insulin requirements were similar across cycles. The distribution of basal versus bolus insulin for each cycle was 63–77% prandial and 23–37% basal. Nine of the 23 patients had at least one glucose value <70 mg/dL, which accounted for 1.3% of all recorded glucose values. None of the patients had severe hypoglycemia. Conclusions: Multiple-dose insulin therapy initiated at 1–1.2 units/kg/day, distributed as 25% basal and 75% prandial, reduced hyperglycemia in patients who were receiving high-dose dexamethasone as part of hyper-CVAD.

1 January 2020 in AACE Clinical Case Reports
Verified
Journal Article
Open access
SBSara Bedrose
Sara Bedrose
CTChristie G. Turin
Christie G. Turin
VLVictor R. Lavis
Victor R. Lavis
SKSang T. Kim
Sang T. Kim
STSonali Thosani
Sonali Thosani
Objective: To describe an unusual immune-related adverse event (irAE), acquired generalized lipodystrophy (AGL), from checkpoint inhibitor therapy in a patient treated with pembrolizumab. ...

4 April 2023 in Immunotherapy
Verified
Journal Article
Closed access
RJRebecca Jeun
Rebecca Jeun
PIPriyanka C Iyer
Priyanka C Iyer
CBConor Best
Conor Best
VLVictor Lavis
Victor Lavis
JVJeena M Varghese
Jeena M Varghese
STSonali Thosani
Sonali Thosani
Introduction: Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate surviv... Plain language summary Cancer treatment with immune checkpoint inhibitors can cause irreversible side effects. In this study, we describe the clinical presentations of 76 patients who developed imm...

22 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AGAyush Gandhi
Ayush Gandhi
RJRebecca Jeun
Rebecca Jeun
ZWZhongya Wang
Zhongya Wang
SKSonya Khan
Sonya Khan
CBConor Best
Conor Best
STSonali Thosani
Sonali Thosani
Background/Objectives: Diabetic ketoacidosis (DKA) is a life-threatening emergency resulting in significant morbidity and health care utilization. The most common cause of DKA in the general population is insulin nonadherence, but limited data exists on precipitating factors for DKA in cancer patients. In this study, we characterize the demographic and clinical characteristics of hospitalized patients with DKA at our comprehensive cancer center. Methods: This single-center retrospective study evaluated 91 patients with 94 admissions for DKA at our institution between January 2019 and December 2021. Demographic, clinical, and biochemical data were obtained from a review of the electronic medical record. Patient characteristics were summarized using descriptive statistics for continuous variables and categorical variables. Results: Of the 91 patients, 21% of patients (n = 19) had underlying type 1 diabetes, 49% of patients (n = 45) had type 2 diabetes, and 30% of patients (n = 27) had drug-induced diabetes. A total of 39% (n = 29) had poorly controlled diabetes with HbA1c > 9% (75 mmol/mol). In patients with known type 1 diabetes, the most common provoking factors were inadequate insulin therapy and infection related causes. In patients with known type 2 diabetes or no previous history of diabetes, the most common provoking factors were medications such as immune checkpoint inhibitors, SGLT2 inhibitors and steroids. Conclusions: We characterized the precipitating factors for DKA based on patients’ underlying diabetes status. While insulin non-adherence was the most common cause in patients with known type 1 diabetes, drugs associated with cancer related treatments emerged most common precipitating factor for DKA in cancer patients with underlying type 2 diabetes or drug induced diabetes. A tailored approach with proactive counseling may be helpful in timely recognition and treatment of DKA in cancer patients.

13 October 2019
Verified
Book Chapter
Closed access
PDF file
SASarimar Agosto
Sarimar Agosto
STSonali Thosani
Sonali Thosani

23 July 2026 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
DODeborah A. Osafehinti
Deborah A. Osafehinti
STSonali Thosani
Sonali Thosani
SWSteven P. Weitzman
Steven P. Weitzman
Background: Continuous glucose monitoring (CGM) is increasingly used in patients with cancer, a population in whom HbA1c may be unreliable. The Glycemia Risk Index (GRI) is a CGM-derived measure integrating hypoglycemia and hyperglycemia risk. We evaluated trends in GRI and other CGM metrics among adults followed in a remote CGM (RCGM) clinic. Methods: Retrospective chart review of adults (≥18 years) with diabetes and cancer seen at a comprehensive cancer center in 2024. Eligible patients had ≥2 CGM assessments (≥1 RCGM) and a baseline glucose management indicator (GMI) or HbA1c ≥8.0%. Generalized linear mixed models examined the effects of visit sequence (time) and RCGM use on GRI, GMI, average glucose, time in range (TIR), time above range (TAR), and time below range (TBR). Pre-specified conservative and liberal noninferiority margins were applied to the remote-use effect. Results: Forty-two patients (mean age 60.2 ± 10.6 years; 95% type 2 diabetes) were included. At baseline, mean GRI was 70 ± 27, GMI 8.5% ± 1.1%, average glucose 214 ± 46 mg/dL, TIR 38% ± 21%, TAR 61% ± 21%, and TBR 1% ± 1%. Across sequential assessments, GRI, GMI, average glucose, and TAR decreased, whereas TIR increased (all P < .05). Remote CGM did not predict any glycemic outcome. Under liberal margins, RCGM was noninferior to nonremote review for GRI, GMI, TIR, and TAR, and noninferior for TBR under both conservative and liberal margins. Conclusions: Sequential CGM review was associated with improved glycemic quality in adults with diabetes and cancer. Remote CGM achieved glycemic outcomes comparable with nonremote review, supporting its use as a viable adjunct to in-person visits in the oncology setting.